astrazeneca glp 1 AstraZeneca’s experimental obesity pill helped patients lose up to 11.8% of their body weight in a mid-stage trial, as competition intensifies in the rapidly growing market for oral weight-loss drugs. The Rise of the GLP-1s:

The growing health crisis drives demand for effective weight loss solutions, including GLP-1 agonists, as healthcare providers seek to address these pressing health challenges

2016 May-Jun;82(3):262-72

Aldhaleei WA, Abegaz TM, Bhagavathula AS

Mind Clarity : It cuts down oxidative stress, sharpening your focus and lifting that mental haze

Results are measurable within 26 weeks: clinical trials show statistically significant reductions in trunk fat with sustained use compared to placebo

The researchers caution that while semaglutide remains a valuable tool for diabetes and obesity management, its use in patients with GLP-1 receptor-positive tumors should be carefully evaluated